Switch to a Long‑Acting Basal Insulin Analog and Reduce the Dose

For an 83‑year‑old woman with type 2 diabetes, CKD stage 3b, and recent severe hypoglycemia on NPH insulin (Humulin I) 20 U morning + 4 U evening, immediately discontinue NPH and initiate a long‑acting basal analog (insulin glargine or detemir) at a reduced total daily dose of approximately 16–18 units once daily at bedtime. 1, 2

Rationale for Switching from NPH to a Basal Analog

NPH insulin has a pronounced peak action 4–12 hours after injection, which substantially raises the risk of hypoglycemia—especially nocturnal hypoglycemia—compared with long‑acting analogs that have a flat, peakless profile. 1, 3
In older adults (>65 years) and those with CKD stage 3b (eGFR ≈32 mL/min/1.73 m²), long‑acting basal analogs (glargine, detemir, or degludec) reduce overall and nocturnal hypoglycemia by 22–58 % compared with NPH insulin when titrated to the same fasting glucose target. 1, 4, 5
A recent severe hypoglycemic episode in this patient signals that the current NPH regimen is unsafe; switching to a basal analog with a more predictable time‑action profile is the standard of care to prevent recurrent hypoglycemia. 1, 5

Initial Dosing Strategy

Calculate the Reduced Total Daily Dose

The patient's current total NPH dose is 24 units/day (20 U morning + 4 U evening). 1, 2
Immediately reduce the total daily dose by 25–30 % (to ≈16–18 units) to account for the recent severe hypoglycemia and the patient's advanced age and renal impairment. 1, 2
For high‑risk patients (age >65 years, CKD stage 3b, recent severe hypoglycemia), guidelines recommend starting basal insulin at 0.1–0.25 units/kg/day; this patient likely weighs ≈60–70 kg, yielding an initial dose of ≈10–18 units once daily. 1, 2

Administer Once Daily at Bedtime

Give the entire reduced dose (16–18 units) of insulin glargine or detemir once daily at bedtime to provide 24‑hour basal coverage while minimizing nocturnal hypoglycemia risk. 1, 2, 3, 6
Bedtime dosing aligns basal insulin activity with overnight fasting glucose and reduces the likelihood of early‑morning hypoglycemia compared with morning administration. 1, 3, 6

Titration Protocol After the Switch

Basal Insulin Titration

Increase the basal analog dose by 2 units every 3 days if fasting glucose is 140–179 mg/dL (7.8–9.9 mmol/L). 1, 2
Increase by 4 units every 3 days if fasting glucose ≥180 mg/dL (≥10 mmol/L). 1, 2
Target fasting glucose: 80–130 mg/dL (4.4–7.2 mmol/L) for most adults; however, in this elderly patient with CKD and hypoglycemia history, a slightly higher target of 100–140 mg/dL (5.6–7.8 mmol/L) may be safer. 1, 2
If any glucose reading falls <70 mg/dL (<3.9 mmol/L), reduce the current basal dose by 10–20 % immediately before the next administration. 1, 2

Monitoring Requirements

Daily fasting glucose checks during the first 2–3 weeks after the switch to guide dose adjustments. 1, 2
Check glucose before meals and at bedtime (minimum 4 times daily) to detect patterns of hypo‑ or hyperglycemia. 1, 2
Reassess renal function (eGFR) every 3–6 months; in CKD stage 3b–4, insulin clearance is reduced, necessitating lower doses and closer monitoring. 1, 5

Safety Considerations in CKD Stage 3b

In patients with CKD stage 3b (eGFR ≈30–45 mL/min/1.73 m²), insulin clearance is reduced by ≈25–50 %, prolonging insulin action and raising hypoglycemia risk. 1, 5
Insulin glargine U100 has been shown to improve glycemic control and reduce nocturnal hypoglycemia by ≈3‑fold in patients with type 2 diabetes and CKD stages 3–4 compared with NPH insulin. 5
Lower starting doses (0.1–0.25 units/kg/day) and conservative titration (2‑unit increments every 3 days) are essential to prevent severe hypoglycemia in this population. 1, 2, 5

Hypoglycemia Management and Prevention

Treat any glucose <70 mg/dL (<3.9 mmol/L) immediately with 15 g of fast‑acting carbohydrate (e.g., 4 glucose tablets or 4 oz juice), recheck in 15 minutes, and repeat if needed. 1, 2
After a hypoglycemic episode, reduce the implicated insulin dose by 10–20 % before the next administration to prevent recurrence. 1, 2
Provide a glucagon emergency kit and educate the patient and caregivers on its use for severe hypoglycemia. 1, 2
Recurrent hypoglycemia can lower glycemic thresholds, making future episodes harder to detect; a 2–3‑week period of strict hypoglycemia avoidance can help restore awareness. 1, 2

Expected Clinical Outcomes

Within 3–7 days of switching to a basal analog at a reduced dose, fasting glucose should stabilize within 100–140 mg/dL without further hypoglycemic episodes. 1, 2, 5
Long‑acting basal analogs provide consistent 24‑hour coverage without the pronounced peak of NPH, reducing nocturnal hypoglycemia by 22–58 % in older adults and those with CKD. 1, 4, 5
HbA1c should remain stable or improve slightly (≈0.5–1.0 % reduction) over 3–6 months with proper titration, while hypoglycemia incidence decreases. 1, 4, 5

Common Pitfalls to Avoid

Do not continue NPH insulin in an elderly patient with CKD and recent severe hypoglycemia; the peaked action profile of NPH makes it unsuitable for this high‑risk population. 1, 5
Do not start the basal analog at the same total daily dose as the previous NPH regimen; a 25–30 % reduction is required to prevent recurrent hypoglycemia. 1, 2
Do not delay switching to a basal analog after a severe hypoglycemic episode; prolonged use of NPH in this setting raises the risk of further dangerous hypoglycemia. 1, 5
Avoid aggressive titration (>2–4 units every 3 days) in elderly patients with CKD; conservative dose escalation is essential to prevent hypoglycemia. 1, 2

Alternative Basal Insulin Options

Insulin detemir is another long‑acting analog with a flat profile and duration of action up to 24 hours; it can be dosed once daily at bedtime in most patients with type 2 diabetes. 7, 6
Insulin degludec is an ultra‑long‑acting analog with a duration of action >42 hours and even lower day‑to‑day variability than glargine or detemir; it may be considered if hypoglycemia remains problematic despite switching to glargine or detemir. 8
All three basal analogs (glargine, detemir, degludec) have been shown to reduce nocturnal hypoglycemia compared with NPH insulin in older adults and those with CKD. 1, 4, 5, 6, 8

Patient Education Essentials

Hypoglycemia recognition and treatment: teach the patient and caregivers to recognize symptoms (shakiness, sweating, confusion) and treat with 15 g fast‑acting carbohydrate. 1, 2
Proper insulin injection technique and site rotation to prevent lipohypertrophy and ensure consistent absorption. 1, 2
Sick‑day management: continue basal insulin even if oral intake is limited, check glucose every 4 hours, and maintain adequate hydration. 1, 2
Glucose monitoring: at least 4 daily measurements (fasting, pre‑meals, bedtime) during the first 2–3 weeks after the switch. 1, 2

Help us tailor your experience